Dr. Jekyll NitroX PixieDust
Dr. Jekyll NitroX PixieDust is categorized as an "Other Combinations" supplement, intended for various support. It received an N+ Score of 64, earning a "D" grade, indicating an average tier product. The product features 5 ingredients with 100% label transparency. Niacin, at 25.000mg, is present at a clinically studied dose, which research suggests may support various metabolic functions. However, Calcium, at 36.000mg, is noted as underdosed for typical daily requirements. The formula includes a Strength & Endurance Matrix (3.500g), Energy & Focus Matrix (625mg), and Pump Matrix (3.600g), but specific ingredient breakdowns within these matrices are not detailed here. This product may appeal to individuals seeking a combination supplement with transparent labeling, despite some ingredients being underdosed.
About This Product
Dr. Jekyll NitroX PixieDust by ProSupps is a joint & bone supplement containing 5 active ingredients. It has earned an N+ Score of 64/100 (Grade D).
Notable clinical-dose ingredients include Niacin.
N+ Score Breakdown
Are key ingredients present at clinically effective doses based on research?
Does the product include all expected ingredients for its supplement category?
Are individual ingredient amounts clearly disclosed without proprietary blends?
Does the formula include a breadth of beneficial compounds from multiple pathways?
Strengths
- +Fully transparent label with individual ingredient amounts disclosed
- +Broad ingredient diversity exceeding category norms
- +1 ingredient(s) at clinical dose levels
Weaknesses
- −Missing several expected ingredients for its category
Ingredient Analysis (5 ingredients)
| Ingredient | Amount | Dose Adequacy |
|---|---|---|
| Niacin | 25.000 mg | Optimal |
| Calcium | 36.000 mg | Under |
| Energy & Focus Matrix | 625.000 mg | N/A |
| Strength & Endurance Matrix | 3.500 Gram(s) | N/A |
| Pump Matrix | 3.600 Gram(s) | N/A |
Clinical ranges based on NIH ODS Fact Sheets and peer-reviewed research. Status indicates whether the amount meets evidence-based thresholds.